Solvaldi Too Expensive? Not To Patients—Gilead Sciences, Inc. Profit Triples On Strong Hep C Drug Sales

Published: Apr 23, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Gilead Sciences, Inc. announced today its results of operations for the quarter ended March 31, 2014. Total revenues for the first quarter of 2014 increased to $5.00 billion from $2.53 billion for the first quarter of 2013. Gilead Sciences Inc. (GILD), with a current value of $112.08B, started the session at $73.00. A quick look at the market, the company’s traded between $71.85 to $73.26 and has traded between $46.70 and $84.88 over the past year.

Help employers find you! Check out all the jobs and post your resume.

Back to news